Amgen

Results: 561



#Item
441

PDF Document

Add to Reading List

Source URL: www.dornc.com

Language: English - Date: 2014-04-16 09:01:50
442

PDF Document

Add to Reading List

Source URL: www.fda.gov

Language: English
443

PDF Document

Add to Reading List

Source URL: www.fda.gov

Language: English
444Page 1  Transcript of FDA’s Media Briefing on Dosing Recommendations for Erythropoiesis Stimulating Agents Moderator: Kimberly Rawlings June 24, 2011

Page 1 Transcript of FDA’s Media Briefing on Dosing Recommendations for Erythropoiesis Stimulating Agents Moderator: Kimberly Rawlings June 24, 2011

Add to Reading List

Source URL: www.fda.gov

Language: English
445Emergence of Biosimilar Medicines The Biosimilar Company Point of View Paul Greenland, Head of Biosimilars Business Unit - EMEA  Belgium Federal Parliament

Emergence of Biosimilar Medicines The Biosimilar Company Point of View Paul Greenland, Head of Biosimilars Business Unit - EMEA Belgium Federal Parliament

Add to Reading List

Source URL: www.egagenerics.com

Language: English
446Microsoft PowerPoint - NYMFSQL MFData[removed]S Myer.ppt

Microsoft PowerPoint - NYMFSQL MFData[removed]S Myer.ppt

Add to Reading List

Source URL: www.ipd.gov.hk

Language: English - Date: 2013-01-07 02:40:51
447      5  Mittwoch, 26. Juni 2013  ·  Nr. 49 8	 Amgen meistert Patentklippe

      5 Mittwoch, 26. Juni 2013  ·  Nr. 49 8 Amgen meistert Patentklippe

Add to Reading List

Source URL: www.kn-portal.com

Language: German - Date: 2013-07-10 07:01:14
    448Pediatric Ethics Subcommittee of the Pediatric Advisory Committee

    Pediatric Ethics Subcommittee of the Pediatric Advisory Committee

    Add to Reading List

    Source URL: www.fda.gov

    Language: English - Date: 2008-12-08 09:50:55
    449Pediatric Ethics Subcommittee of the Pediatric Advisory Committee

    Pediatric Ethics Subcommittee of the Pediatric Advisory Committee

    Add to Reading List

    Source URL: www.fda.gov

    Language: English - Date: 2008-12-03 13:16:49
    450INTERIM DOCUMENT  Facts About Neupogen® When a person has received a very high dose of radiation, destruction of the bone marrow, potentially resulting in uncontrolled bleeding and infection, is a major concern. To help

    INTERIM DOCUMENT Facts About Neupogen® When a person has received a very high dose of radiation, destruction of the bone marrow, potentially resulting in uncontrolled bleeding and infection, is a major concern. To help

    Add to Reading List

    Source URL: www.bt.cdc.gov

    Language: English - Date: 2006-10-26 16:22:37